Clinical trials: open to volunteers, sponsored by Ruijin Hospital
Gastric Cancer (GC)
GK01 Cell Therapy in Gastric Cancer With Peritoneal Metastasis
This study is a single-arm, open-label clinical study designed to evaluate the safety, tolerability, and preliminary efficacy of GK01 cell therapy in patients with gastric cancer and peritoneal metastasis.
- Trial name
- NCT07923396
- Testing
- GK01 combination with nab-paclitaxel and S-1
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Ruijin Hospital
HER2-mutant Advanced Non-Small Cell Lung Cancer
Real-World Outcomes of Sevabertinib in HER2-Mutant Advanced NSCLC: A Bidirectional Cohort Study
This is a single-center, observational, bidirectional cohort study evaluating the real-world effectiveness, safety, and quality of life associated with sevabertinib in Chinese adults with HER2-mutant advanced non-small cell lung…
- Trial name
- NCT07880353
- Testing
- Sevabertinib
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Ruijin Hospital
Non-Small Cell Lung Cancer
Proton Moderately Hypofractionated Radiotherapy in NSCLC Patients Unable to Tolerate Standard Concurrent Chemoradiotherapy
The goal of this clinical trial is to learn if proton moderately hypofractionated radiotherapy works to treat non-small cell lung cancer in adults who cannot tolerate standard concurrent chemoradiotherapy.
- Trial name
- NCT07919691
- Testing
- Proton radiotherapy
- Volunteers
- 44 people
- Sponsor
- Ruijin Hospital
Pancreatic Mucinous Cystic Neoplasm, Pancreatic Serous Cystic Neoplasm
AI-Assisted Differentiation of Pancreatic Cystic Lesions Using EUS Images and Clinical Features
Pancreatic mucinous cystic neoplasms (MCNs), serous cystic neoplasms (SCNs), and pancreatic pseudocysts (PPCs) often exhibit overlapping imaging features on endoscopic ultrasound (EUS).
- Conditions
- Pancreatic Mucinous Cystic Neoplasm, Pancreatic Serous Cystic Neoplasm, Pancreatic Pseudocyst
- Trial name
- NCT07919704
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Ruijin Hospital
Atrial Fibrillation (Persistent), Catheter Ablation
Sacubitril/Valsartan vs Standard Treatment for Preventing Atrial Fibrillation Recurrence After Catheter Ablation in Persistent Atrial Fibrillation Patients With Without Hypertension
The goal of this clinical trial is to investigate the efficacy and safety of angiotensin receptor-neprilysin inhibitor (sacubitril/valsartan) in preventing recurrence of atrial fibrillation after catheter ablation in…
- Conditions
- Atrial Fibrillation (Persistent), Catheter Ablation, Non-hypertension, Angiotensin Receptor/Neprilysin Inhibitor
- Trial name
- SUPERIOR 2 (NCT07910058)
- Testing
- Sacubitril/Valsartan, Standard Care
- Volunteers
- 472 people
- Sponsor
- Ruijin Hospital
Malignant Pleural Mesothelioma, Advanced
Efficacy and Safety of Ivonescimab Plus Pemetrexed and Platinum-Based Chemotherapy in Advanced Malignant Pleural Mesothelioma
This Phase 1b/2, open-label, multicenter, single-arm study evaluates the safety and efficacy of ivonescimab in combination with pemetrexed and platinum-based chemotherapy as first-line treatment for advanced malignant pleural…
- Trial name
- NCT07885319
- Testing
- Ivonescimab Combined With Chemotherapy
- Where
- 3 sites in China
- Volunteers
- 78 people
- Sponsor
- Ruijin Hospital
Non-Small Cell Lung Cancer
Risk-Adapted Segmental Esophagus-Sparing Radiotherapy for Definitive Non-Small Cell Lung Cancer
This is a multicenter, open-label, randomized, phase 3 superiority trial. The purpose is to find out whether a risk-adapted segmental esophagus-sparing radiotherapy plan is better than a standard radiotherapy plan at reducing…
- Trial name
- ES-SPARE (NCT07908732)
- Testing
- Risk-Adapted Segmental Esophagus-Sparing IMRT/VMAT, Standard IMRT/VMAT Without Active Esophageal Avoidance
- Volunteers
- 140 people
- Sponsor
- Ruijin Hospital
Non-Small-Cell Lung Cancer
Reduced-Dose vs Standard-Dose Thoracic Radiotherapy After Induction Chemoimmunotherapy in Older or Frail Stage III NSCLC
This is a multicenter, open-label, randomized phase III study in older or frail adults with unresectable stage III non-small cell lung cancer (NSCLC) who are considered unsuitable for concurrent chemoradiotherapy.
- Trial name
- NCT07908745
- Testing
- Reduced-Dose Thoracic Radiotherapy, Standard-Dose Thoracic Radiotherapy
- Volunteers
- 276 people
- Sponsor
- Ruijin Hospital
Cholangitis, Ascending Cholangitis
Rifaximin for Prevention of Recurrent Mild-to-moderate Ascending Cholangitis After Biliary-enteric Anastomosis
This single-center prospective randomized controlled trial plans to recruit 60 adult patients with recurrent ascending cholangitis after biliary-enteric anastomosis.
- Trial name
- NCT07895433
- Testing
- Rifaximin combined with standard care, Standard Care (in control arm)
- Volunteers
- 60 people
- Sponsor
- Ruijin Hospital
Thrombocytopenia
A Clinical Study Evaluating the Safety and Preliminary Effectiveness of Induced Pluripotent Stem Cell-derived Platelets in Patients With Thrombocytopenia Caused by Allogeneic Hematopoietic Stem Cell Transplantation
A multicenter open-label study with dose-escalation and multiple expansion cohorts, aimed at evaluating the safety and preliminary efficacy of IPSC-derived platelets in patients with thrombocytopenia caused by allogeneic…
- Trial name
- NCT07905144
- Testing
- iPSC-derived platelets
- Volunteers
- 9 people
- Sponsor
- Ruijin Hospital
Myeloid Neoplasms With Myelofibrosis
An Exploratory Study on the Use of Gecacitinib in Patients With Myeloid Malignancies and Myelofibrosis During the Peri-transplant Period Following Allogeneic Hematopoietic Stem Cell Transplantation
This is a single-arm, single-center exploratory study evaluating the safety and efficacy of gecacitinib administered in the peri-transplant period in patients with myeloid neoplasms and myelofibrosis (MF) who are scheduled to…
- Trial name
- JAK-PeriMF (NCT07883382)
- Testing
- gecacitinib Hydrochloride Tablets
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Ruijin Hospital
Autoimmune Pancreatitis, Pancreatic Ductal Adenocarcinoma (PDAC)
AI-Assisted Differentiation of Autoimmune Pancreatitis and Pancreatic Cancer Using EUS: A Multicenter Ambispective Study
Focal autoimmune pancreatitis (f-AIP) and pancreatic ductal adenocarcinoma (PDAC) exhibit substantial overlap in clinical manifestations and imaging features, posing a major diagnostic challenge in pancreatic diseases.
- Trial name
- NCT07900776
- Volunteers
- 690 people
- Sponsor
- Ruijin Hospital
Coronary Artery Bypass, Radial Artery Grafts
Fasciotomy and Predilation for Radial Artery Grafts in CABG
The goal of this clinical trial is to learn if a new way to prepare a radial artery graft during coronary artery bypass grafting (CABG) can improve outcomes for adults having this surgery.
- Trial name
- RAPID-CABG (NCT07868692)
- Testing
- Radial Artery Harvesting With Fasciotomy and Predilation, Radial Artery Harvesting Without Fasciotomy or Predilation
- Where
- China
- Volunteers
- 314 people
- Sponsor
- Ruijin Hospital
ARDS (Acute Respiratory Distress Syndrome), Respiratory Failure
Development and Prospective Validation of the AutoEIT Foundation Model for ARDS
Acute Respiratory Distress Syndrome (ARDS) is a highly heterogeneous condition, making precision mechanical ventilation challenging.
- Conditions
- ARDS (Acute Respiratory Distress Syndrome), Respiratory Failure, Mechanical Ventilation, Ventilator-induced Lung Injury (VILI)
- Trial name
- NCT07898319
- Testing
- AutoEIT Model Training, AutoEIT Blinded Validation
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- Ruijin Hospital
Coronary Artery Disease, Coronary Artery Bypass Grafting
CCTA-Based vs CAG-Based CABG: A Multicenter Pragmatic Non-Inferiority Trial
The goal of this clinical trial is to find out if using a non-invasive heart scan (called coronary computed tomography angiography, or CCTA) to plan coronary artery bypass grafting (CABG) works as well as the standard invasive…
- Conditions
- Coronary Artery Disease, Coronary Artery Bypass Grafting, Coronary Computed Tomography Angiography, Coronary Angiography (CAG)
- Trial name
- CtaCAB (NCT07769008)
- Testing
- CCTA-based CABG, CAG-based CABG
- Where
- China
- Volunteers
- 826 people
- Sponsor
- Ruijin Hospital
Esophageal Cancer
Modular Robot-Assisted Versus Conventional Minimally Invasive Esophagectomy for Esophageal Cancer
This study evaluates the safety, efficacy, and health economic outcomes of modular robotic-assisted minimally invasive esophagectomy (RAMIE) compared with conventional thoracoscopic minimally invasive esophagectomy (MIE) in…
- Trial name
- mRAMIE2026 (NCT07888140)
- Testing
- Modular Robot-Assisted Esophagectomy, Conventional Minimally Invasive Esophagectomy
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Ruijin Hospital
Urothelial Carcinoma (UC), Upper Tract Urothelial Carcinoma
Urinary Cell-Free DNA Liquid Biopsy for Urothelial Cancer Diagnosis and Origin Identification
Urothelial carcinoma is the most common cancer of the urinary system. It includes bladder cancer and upper urinary tract cancer, which starts in the kidney pelvis or ureter.
- Conditions
- Urothelial Carcinoma (UC), Upper Tract Urothelial Carcinoma, Bladder Cancer
- Trial name
- NCT07888374
- Where
- China
- Volunteers
- 477 people
- Sponsor
- Ruijin Hospital
Rectal Neoplasms, Rectal Cancer, Adenocarcinoma
SCRT + Fruquintinib + Tislelizumab + CAPOX Versus SCRT + Tislelizumab + CAPOX as Neoadjuvant Therapy for Locally Advanced Low Rectal Cancer
The goal of this randomized controlled clinical trial is to learn if adding fruquintinib to short-course radiotherapy, tislelizumab, and CAPOX can improve neoadjuvant treatment response and is safe for adults with locally…
- Trial name
- TRIP-FAST (NCT07888309)
- Testing
- Short-Course Radiotherapy, Fruquintinib, Tislelizumab
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Ruijin Hospital
Primary IgA Nephropathy
Efficacy and Safety of Obinutuzumab Beta in Primary IgA Nephropathy With Active Pathological Lesions
The goal of this clinical trial is to evaluate if obinutuzumab beta works to treat primary IgA nephropathy with active proliferative lesions in adults. It will also learn about the safety of obinutuzumab beta.
- Trial name
- NCT07888335
- Testing
- Obinutuzumab Beta
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Ruijin Hospital
Lung Neoplasm Malignant
Adebrelimab Plus Famitinib as Adjuvant Therapy in Non-pCR NSCLC
Neoadjuvant immunotherapy combined with chemotherapy followed by surgery has become an important treatment strategy for resectable non-small cell lung cancer (NSCLC).
- Trial name
- NCT07890636
- Testing
- Adebrelimab, Adjuvant treatment
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Ruijin Hospital